Arkolith/Insider Trading/CTNM/Form 4

Stengone Carmine N.

CEO and President, DirectorContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Jul 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$160K
Net Open-Market Flow
-$160K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)8K$1.01$8K25K
Jun 30, 2026Option exercise(M)3K$1.26$3K27K
Jun 30, 2026Sell(S)10K$16.01$160K17K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)8K—$0282K
Jun 30, 2026Option exercise(M)3K—$0118K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-046653) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML